title: [Multi-central clinical evaluation of ginger-partitioned moxibustion for treatment of leukopenia induced by chemotherapy].
abstract: OBJECTIVE
  To prove the therapeutic effect of ginger-partitioned moxibustion on leukopenia induced by chemotherapy and effect on life quality of the patient with tumor after chemotherapy.
  
  
  METHODS
  Randomized, controlled, multi-central cooperative method was used and the patients confirmed to the enrolled criteria were divided in-to two groups. The test group were treated with ginger-partitioned moxibustion at Dazhui (GV 14), Geshu (BL 17), Pishu (BL 20), etc.; and the control group with oral administration of Chinese patent medicine.
  
  
  RESULTS
  Out of the 221 cases confirmed to program analysis, 113 cases were in the test group and 108 cases in the control group. After 10 days, the cured rate and the effective rate were 84.1% and 66.4% in the test group and 35.2% and 33.3% in the control group, respectively, with very significant differences between the two groups (both P < 0.01); fifteen days later, the therapeutic effects in the two groups were maintained. The two methods could improve clinical symptoms, with the test group being better than the control group. Any adverse response was not found in the two groups, and the injuries of functions of the heart, lung and kidney induced by chemotherapy had some improvement.
  
  
  CONCLUSIONS
  The therapeutic effect of ginger-partitioned moxibustion on luekopenia induced by chemotherapy is reliable and is better than oral administration of Chinese patent medicine, with a better duplication.
authors.affiliation: The Third Affiliated Hospital, College of TCM of Henan, Zhengzhou 450008, China. zhaoxixin10@yahoo.com.cn
authors.forename: Xi-Xin
authors.initials: XX
authors.lastname: Zhao
authors.forename: Mei
authors.initials: M
authors.lastname: Lu
authors.forename: Xia
authors.initials: X
authors.lastname: Zhu
authors.forename: Ping
authors.initials: P
authors.lastname: Gao
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Li
authors.forename: Xue-Mei
authors.initials: XM
authors.lastname: Wang
authors.forename: Dong-Yang
authors.initials: DY
authors.lastname: Ma
authors.forename: Xian-Hui
authors.initials: XH
authors.lastname: Guo
authors.forename: Bo-Ying
authors.initials: BY
authors.lastname: Tong
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Yang
authors.forename: Wei-Wei
authors.initials: WW
authors.lastname: Du
authors.forename: Shi-Fan
authors.initials: SF
authors.lastname: Zhou
authors.forename: Huai-Min
authors.initials: HM
authors.lastname: Liu
authors.forename: Peng-Fei
authors.initials: PF
authors.lastname: Ran
authors.forename: Xiao-Rui
authors.initials: XR
authors.lastname: Lü
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D020939:Zingiber officinale; D006801:Humans; D007970:Leukopenia / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009071:Moxibustion / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents